ULTRAGENYX PHARMACEUTICAL INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $46.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $46.00M, a 14.81% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $54.00M, a 10.00% decline from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $60.00M, a 2.25% increase from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $58.68M, a 21.99% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $46.00M 10-K · filed 2026-02-18 | |
| 2024-12-31 | $54.00M 10-K · filed 2026-02-18 | $53.84M 10-K · filed 2025-02-19 |
| 2023-12-31 | $60.00M 10-K · filed 2026-02-18 | $59.70M 10-K · filed 2024-02-21 |
| 2022-12-31 | $58.68M 10-K · filed 2025-02-19 | $58.70M 10-K · filed 2023-02-17 |
| 2021-12-31 | $48.10M 10-K · filed 2024-02-21 | |
| 2020-12-31 | $45.40M 10-K · filed 2023-02-17 | |
| 2019-12-31 | $45.30M 10-K · filed 2022-02-15 | |
| 2018-12-31 | $51.70M 10-K · filed 2021-02-12 | |
| 2017-12-31 | $49.10M 10-K · filed 2020-02-14 | |
| 2016-12-31 | $43.80M 10-K · filed 2019-02-20 | |
| 2015-12-31 | $10.70M 10-K · filed 2018-02-21 | |
| 2014-12-31 | $2.00M 10-K · filed 2017-02-17 | |
| 2013-12-31 | $100.00K 10-K · filed 2016-02-26 | $127.00K 10-K · filed 2015-03-27 |
| 2012-12-31 | $172.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |